NewLimit secures $130M to pursue age-reversing therapies using AI and cellular reprogramming
Biotech startup NewLimit, co-founded by Coinbase CEO Brian Armstrong, has secured a $130 million Series B to develop treatments that could reverse cellular aging.

The best Articles in our Network